731 related articles for article (PubMed ID: 18381423)
21. Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma.
Owen LA; Lessnick SL
Cell Cycle; 2006 Sep; 5(18):2049-53. PubMed ID: 16969112
[TBL] [Abstract][Full Text] [Related]
22. The Biology of Ewing sarcoma.
Riggi N; Stamenkovic I
Cancer Lett; 2007 Aug; 254(1):1-10. PubMed ID: 17250957
[TBL] [Abstract][Full Text] [Related]
23. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.
Cironi L; Riggi N; Provero P; Wolf N; Suvà ML; Suvà D; Kindler V; Stamenkovic I
PLoS One; 2008 Jul; 3(7):e2634. PubMed ID: 18648544
[TBL] [Abstract][Full Text] [Related]
24. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
25. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
27. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.
Braunreiter CL; Hancock JD; Coffin CM; Boucher KM; Lessnick SL
Cell Cycle; 2006 Dec; 5(23):2753-9. PubMed ID: 17172842
[TBL] [Abstract][Full Text] [Related]
28. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
[TBL] [Abstract][Full Text] [Related]
29. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation.
Li X; McGee-Lawrence ME; Decker M; Westendorf JJ
J Cell Biochem; 2010 Nov; 111(4):933-43. PubMed ID: 20665663
[TBL] [Abstract][Full Text] [Related]
30. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
Owen LA; Kowalewski AA; Lessnick SL
PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
[TBL] [Abstract][Full Text] [Related]
31. EWS-FLI1 causes neuroepithelial defects and abrogates emigration of neural crest stem cells.
Coles EG; Lawlor ER; Bronner-Fraser M
Stem Cells; 2008 Sep; 26(9):2237-44. PubMed ID: 18556509
[TBL] [Abstract][Full Text] [Related]
32. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G
Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330
[TBL] [Abstract][Full Text] [Related]
33. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.
Chansky HA; Barahmand-Pour F; Mei Q; Kahn-Farooqi W; Zielinska-Kwiatkowska A; Blackburn M; Chansky K; Conrad EU; Bruckner JD; Greenlee TK; Yang L
J Orthop Res; 2004 Jul; 22(4):910-7. PubMed ID: 15183454
[TBL] [Abstract][Full Text] [Related]
34. Detection of EWS/FLI-1 fusion in non-Ewing soft tissue tumors.
Trancău IO; Huică R; Surcel M; Munteanu A; Ursaciuc C
J Med Life; 2015; 8(1):85-9. PubMed ID: 25914746
[TBL] [Abstract][Full Text] [Related]
35. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
36. EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model.
Peng W; Huang X; Yang D
Int Immunopharmacol; 2014 Aug; 21(2):336-41. PubMed ID: 24861249
[TBL] [Abstract][Full Text] [Related]
37. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
38. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profile of ewing sarcoma cell lines differing in their EWS-FLI1 fusion type.
Bandrés E; Malumbres R; Escalada A; Cubedo E; González I; Honorato B; Zarate R; García-Foncillas J; de Alava E
J Pediatr Hematol Oncol; 2005 Oct; 27(10):537-42. PubMed ID: 16217257
[TBL] [Abstract][Full Text] [Related]
40. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.
Abaan OD; Levenson A; Khan O; Furth PA; Uren A; Toretsky JA
Oncogene; 2005 Apr; 24(16):2715-22. PubMed ID: 15782144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
